Eric W Hoffman
Overview
Explore the profile of Eric W Hoffman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smaletz O, Ismael G, Estevez-Diz M, Nascimento I, Gomes de Morais A, Cunha-Junior G, et al.
Int J Gynecol Cancer
. 2021 Mar;
31(4):562-568.
PMID: 33664128
Objective: To investigate the efficacy and safety of hu3S193, a humanized anti-Lewis-Y monoclonal antibody, as a consolidation strategy in patients with platinum-sensitive recurrent epithelial ovarian cancer who achieved a second...
2.
Hoffman E, Austin E, Pinkleton B, Austin B
Health Commun
. 2016 Jul;
32(7):864-871.
PMID: 27421038
College students' use of digital communication technology has led to a rapid expansion of digital alcohol marketing efforts. Two surveys (total usable n = 637) were conducted to explore college...
3.
Smaletz O, Diz M, do Carmo C, Sabbaga J, Cunha-Junior G, Azevedo S, et al.
Gynecol Oncol
. 2015 Jun;
138(2):272-7.
PMID: 26026738
Objectives: The primary objective was to evaluate the clinical efficacy of hu3S193, a humanized monoclonal antibody against the Lewis-Y antigen, in patients with platinum resistant/refractory ovarian, fallopian tube and primary...
4.
Hoffman E, Pinkleton B, Austin E, Reyes-Velazquez W
J Am Coll Health
. 2014 Mar;
62(5):328-35.
PMID: 24635485
Objective: Alcohol marketers have increasingly moved their advertising efforts into digital and social media venues. As a result, the purpose of this study is to investigate associations between students' use...
5.
Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al.
Clin Cancer Res
. 2012 Oct;
18(23):6497-508.
PMID: 23032745
Purpose: Long peptides are efficiently presented to both CD4(+) and CD8(+) T cells after intracellular processing by antigen-presenting cells. To investigate the safety and in vivo immunogenicity of synthetic overlapping...
6.
Ott P, Carvajal R, Pandit-Taskar N, Jungbluth A, Hoffman E, Wu B, et al.
Invest New Drugs
. 2012 Aug;
31(2):425-34.
PMID: 22864522
Background Arginine deiminase (ADI) is an enzyme that degrades arginine, an amino acid that is important for growth and development of normal and neoplastic cells. Melanoma cells are auxotrophic for...
7.
Nicholaou T, Chen W, Davis I, Jackson H, Dimopoulos N, Barrow C, et al.
Cancer Immunol Immunother
. 2011 Jun;
60(11):1625-37.
PMID: 21698545
Background: NY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients...
8.
Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, et al.
Int J Cancer
. 2011 Mar;
129(12):2836-46.
PMID: 21448901
We conducted a phase I clinical trial of a cancer vaccine using a 20-mer NY-ESO-1f peptide (NY-ESO-1 91-110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T...
9.
Nicholaou T, Ebert L, Davis I, McArthur G, Jackson H, Dimopoulos N, et al.
Clin Cancer Res
. 2009 Mar;
15(6):2166-73.
PMID: 19276262
Purpose: NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently developed a vaccine consisting of full-length recombinant...
10.
Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, et al.
Int J Cancer
. 2008 Aug;
123(10):2362-9.
PMID: 18729190
NY-ESO-1 antigen is a prototype of a class of cancer/testis antigens. We carried out a clinical trial using NY-ESO-1 whole protein as a cancer vaccine for 13 advanced cancer patients....